Recent Articles
FDA Places Clinical Hold on LentiGlobin Gene Therapy Trials
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on all LentiGlobin gene therapy trials following an announcement that two participants...
Melphalan Flufenamide Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients...
Trilaciclib Approved for Chemotherapy-Induced Myelosuppression
The U.S. Food and Drug Administration (FDA) has approved trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, to reduce the frequency of bone marrow suppression in...
Novartis and the Gates Foundation Collaborate on Off-the-Shelf Gene Therapy for Sickle Cell Disease
Novartis and the Bill and Melinda Gates Foundation are collaborating on a one-step, one-time gene therapy for patients with sickle cell disease (SCD). The...
‘All of Us’ Technology Platform Aims to Democratize Research
All of Us, a $1.5 billion National Institutes of Health (NIH) initiative to collect DNA and health data on one million Americans from diverse...
Current Issue
March 2021 Volume 7 Issue 4
This issue examines the 21st Century Cures Act’s information blocking requirements, blood services around the globe, and more.